Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cell-cycle inhibition is a developing strategy for cancer treatment, but comprehensive evaluations of inhibitor combinations are lacking.
• Aberrant expression of Cyclin A2, a key cell cycle regulator, is common in cancers and may influence tumor cell proliferation.
• Cyclin A2 functions with Cyclin-dependent kinase 2 (Cdk2) in cell cycle progression.

Purpose of the Study:

• To investigate the role of Cyclin A2 in tumorigenesis using a conditional genetic knockout mouse model.
• To explore the contribution of Cdk2 dysregulation to the observed effects of Cyclin A2 deletion.
• To evaluate the therapeutic potential of targeting Cyclin A2 and Cdk2 in cancer.

Main Methods:

• Utilized a conditional genetic knockout mouse model to delete Cyclin A2 in oncogene-transformed mouse embryonic fibroblasts (MEFs) and hepatocytes.
• Performed conditional gene deletions of both Cyclin A2 and Cdk2 in oncogene-transformed MEFs.
• Assessed tumor formation, cell proliferation, senescence, and recovery from serum deprivation.

Main Results:

• Cyclin A2 deletion suppressed tumor formation in MEFs and delayed liver tumor formation in hepatocytes.
• Simultaneous deletion of Cyclin A2 and Cdk2 strongly suppressed tumor formation, associated with reduced proliferation and increased premature senescence.
• Loss of Cyclin A2 led to compensatory Cdk1 activity, which was not observed when both Cdk2 and Cyclin A2 were deleted.

Conclusions:

• Cyclin A2 plays a significant role in tumorigenesis.
• Combined inhibition of Cdk2 and Cyclin A2 effectively suppresses tumor growth.
• The findings provide a rationale for exploring combined Cdk1 and Cdk2 inhibitors as a cancer therapy approach.